tradingkey.logo

Arvinas And Pfizer Announce Positive Topline Results From Phase 3 Veritac-2 Clinical Trial

ReutersMar 11, 2025 10:46 AM

- Arvinas Inc ARVN.O:

  • ARVINAS AND PFIZER ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 VERITAC-2 CLINICAL TRIAL

  • ARVINAS INC - VERITAC-2 ACHIEVES PRIMARY ENDPOINT IN ESR1M POPULATION

  • ARVINAS INC - TRIAL DID NOT REACH STATISTICAL SIGNIFICANCE IN ITT POPULATION

  • ARVINAS INC - VEPDEGESTRANT GENERALLY WELL TOLERATED WITH CONSISTENT SAFETY PROFILE

  • ARVINAS INC - TRIAL TO CONTINUE ASSESSING OVERALL SURVIVAL AS SECONDARY ENDPOINT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI